Navigation Links
Today's Research on Celsion, Zogenix, Actavis, and Avanir Pharma

LONDON, April 10, 2013 /PRNewswire/ --

One of the major trends to emerge in the healthcare industry in the last year has been the expiration of patents on several blockbuster drugs. This had led to increasing competition from generic drug companies such as Actavis Inc. (NYSE: ACT) and Avanir Pharmaceuticals Inc. (NASDAQ: AVNR). For major drug manufacturers such as Zogenix Inc. (NASDAQ: ZGNX), the key will be to continue to boost their product pipeline. Major drug manufacturers are also likely to collaborate with biotechnology companies such as Celsion Corporation (NASDAQ: CLSN) that are developing or have developed potential blockbuster drugs. On Tuesday, healthcare stocks ended on a mixed note even as the broad market posted significant gains. StockCall professionals have completed their technical analysis on CLSN, ZGNX, ACT, and AVNR and these free reports are accessible by registering at  

Shares of Celsion Corporation edged higher yesterday; however, the gains were limited. The stock touched an intra-day high of $1 before finishing the day 0.41% higher at $0.974 on volume of 523,658. Despite the gains on Tuesday, Celsion's shares have fallen more than 4.50% in the last three trading sessions. Year-to-date, the stock has lost more than 88% of its value. Most of the losses came in February when the stock saw a steep decline. In the last one month, shares of CLSN have traded sideways, struggling to break through $1 level. Sign up for the free technical research on CLSN at

Shares of Zogenix Inc. saw a sharp decline in trading on Tuesday. The stock ended the day 2.52% lower at $1.55 on volume of 515,540. The stock has now fallen more than 13.40% in the last three trading sessions. The major drug maker's shares have fallen sharply after the stock failed to break through $2 resistance level. The stock recently slipped below $1.60 support level, and also its 50-day moving average. This suggests that market sentiment is currently bearish on the stock. The downbeat trend is further confirmed by the stock's MACD chart. Be sure to read our latest technical research on ZGNX by registering at

Actavis Inc.'s shares ended marginally lower on Tuesday. The stock touched a 52-week high of $98.46 earlier in the day; however, it failed to hold onto its gains. Actavis' shares ended the day 0.66% lower at $97.71 on volume of 1.10 million. Despite the losses yesterday, the generic drug maker's shares are still up nearly 2% in the last three trading sessions. The stock has had an excellent run so far in 2013, gaining more than 13.60%. The company's shares have seen a series of highs since last month, which is a bullish signal. Sign up and read the complimentary report on ACT at

Avanir Pharmaceuticals Inc.'s shares were among the major gainers in the healthcare sector on Tuesday. The stock closed 2.65% higher at $2.71 on volume of 594,199 after touching an intra-day high of $2.77. Avanir's shares are currently trading more than 33% below their 52-week high. The stock bounced back yesterday after seeing a series of lows in the past two weeks. Shares of this generic drug maker are still trading well below their 50-day and 200-day moving averages, which is a bearish signal. The negative trend is further confirmed by the stock's MACD chart.  The free report on AVNR can be downloaded by signing up now at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at  

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
2. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
3. St. Johns Research Institute Honored by Waters Center of Innovation Program
4. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
5. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at
6. Manchester leads the way in graphene membrane research
7. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
8. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
9. Solution Styrene Butadiene Rubber (S-SBR) Market is Expected to Reach USD 3.2 Billion in 2018: Transparency Market Research
10. Elsevier and the Belarus Ministry of Education Honor Researchers with Scopus Awards
11. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
Post Your Comments:
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and ... as Chief Operating Officer. , Having joined InSphero in November 2013 as ... promoted to Head of InSphero Diagnostics in 2014. There she has built up ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
Breaking Biology News(10 mins):